COVID-19 as a Catalyst for Innovation: Pharmaceutical Industry Manufacturing Techniques and Management of Endemic Diseases
DOI:
https://doi.org/10.47709/ijmdsa.v2i2.2996Keywords:
Global risk mitigation in supply chain, embedded readiness solutions, large scale production solutions, localized production centers, standardized policy structures, new disease threats, current pandemic, pharma industries manufacturing, manufacturing based platforms.Abstract
The lockdown measures of the Covid-19 pandemic have significantly impacted change in pharmaceutical manufacturing technology, regulation and global supply chains. To respond to unprecedented global demand, significant advances took place and these include platform-based manufacturing such as mRNA and viral vector vaccines, shift to continuous manufacture. Indeed, reducing harm to the buying public through the preservation of product safety and quality, the regulatory modifications such as the EUAs and concurrent process validation accelerated the approvals of vaccines. To achieve the effective knowledge transfer for collaboration like COVAX, the fair distribution of vaccinations for every country in the world was ensured. The fact is that all these concerns will be crucial for maintaining the preparedness for other future health threats in case the pandemic turns into the endemic phase. If the pharmaceutical sector is to make greater investments in scalable production technology, regional manufacturing events and unified regulations they will be in a position to respond to new public health threats in a more efficient manner. In this abstract, the author discusses the lessons learned and their relevance in future global threats and emphasizes the transformative nature of COVID-19 in the generation of pharmacy manufacture.
References
Lee NK, Wang CPJ, Lim J, Park W, Kwon HK, Kim SN, et al. Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities. Nano Converg. 2021 Dec 1; 8(1).
Wang Z, Popowski KD, Zhu D, de Juan Abad BL, Wang X, Liu M, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat Biomed Eng. 2022 Jul 1; 6(7):791–805.
Sliepen K, Radi? L, Capella-Pujol J, Watanabe Y, Zon I, Chumbe A, et al. Induction of crossneutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Nat Commun. 2022 Dec 1; 13(1).
Durigutto P, Macor P, Ziller F, de Maso L, Fischetti F, Marzari R, et al. Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. PLoS One. 2013 Mar 7; 8(3).
Tang Z, Veillete A. Improving treatment of solid cancers by nnoconjugate-mediated immune conversion of tumour cells. Nat Nanotechnol. 2022 Dec 10;
Liu Q, Duo Y, Fu J, Qiu M, Sun Z, Adah D, et al. Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. Vol. 36, Nano Today. Elsevier B.V.; 2021.
Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano. 2021 Aug 2;
Mota AH, Sousa A, Figueira M, Amaral M, Sousa B, Rocha J, et al. Natural-based consumer health nanoproducts: Medicines, cosmetics, and food supplements. In: Handbook of Functionalized Nanomaterials for Industrial Applications. Elsevier; 2020. p. 527–78. 19.
Pietersz GA, Wang X, Yap ML, Lim B, Peter K. Therapeutic targeting in nanomedicine: The future lies in recombinant antibodies. Vol. 12, Nanomedicine. Future Medicine Ltd.; 2017. p. 1873–89.
WIilhem S. Analysis of nanoparticle delivery to tumors [Internet]. Available from: www.nature.com/natrevmats
Julien DC, Behnke S, Wang G, Murdoch GK, Hill RA. Utilization of monoclonal antibodytargeted nanomaterials in the treatment of cancer. Vol. 3, mAbs. 2011. p. 467–78.
Nevala WK, Buhrow SA, Knauer DJ, Reid JM, Atanasova EA, Markovic SN. Antibodytargeted chemotherapy for the treatment of melanoma. Cancer Res. 2016 Jul 1; 76(13):3954–64.
Nisini R, Poerio N, Mariotti S, de Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Vol. 9, Frontiers in Immunology. Frontiers Media S.A.; 2018.
Qu X, Zhou D, Lu J, Qin D, Zhou J, Liu HJ. Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, 57 immunotherapy, and phototherapy. Vol. 24, Bioactive Materials. KeAi Communications Co.; 2023. p. 136–52.
Yang Z, Gao D, Yang G, Guo M, Wang Y, Ren X, et al. Thermal immuno-nanomedicine in cancer. Nat Rev Clin Oncol. 2023 Jan 5;
He T, Hu M, Zhu S, Shen M, Kou X, Liang X, et al. A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence. Acta Pharm Sin B. 2023 Feb 1; 13(2):804–18.
Badrinath N, Heo J, Yoo SY. Viruses as nanomedicine for cancer. Vol. 11, International Journal of Nanomedicine. Dove Medical Press Ltd.; 2016. p. 4835–47.
DuRoss AN, Neufeld MJ, Rana S, Thomas CR, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Vol. 144, Advanced Drug Delivery Reviews. Elsevier B.V.; 2019. p. 35–56.
Khatun S, Putta CL, Hak A, Rengan AK. Immunomodulatory nanosystems: An emerging strategy to combat viral infections. Vol. 9, Biomaterials and Biosystems. Elsevier Ltd; 2023.
Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020 May 1; 15(5):406–16.
Priya Dharshini K, Ramya Devi D, Banudevi S, Vedha VH. In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV. Sci Rep. 2022 Dec 1; 12(1).
Dvir T, Timko BP, Kohane DS, Langer R. Nanotechnological strategies for engineering complex tissues. Vol. 6, Nature Nanotechnology. Nature Publishing Group; 2011. p. 13–22.
Galetti M, Rossi S, Caffarra C, Gerboles AG, Miragoli M. Chapter 9 - Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes. In: Exposure to Engineered Nanomaterials in the Environment. Elsevier; 2019. p. 235–62.
Yang B, Yao H, Yang J, Chen C, Shi J. Construction of a two-dimensional artificial antioxidase for nanocatalytic rheumatoid arthritis treatment. Nat Commun. 2022 Dec 1; 13(1).
Gangrade A, Stephanopoulos N, Bhatia D. Programmable, self-assembled DNA nanodevices for cellular programming and tissue engineering. Vol. 13, Nanoscale. Royal Society of Chemistry; 2021. p. 16834–46.
Marino A, Battaglini M, Tapeinos C, Larrañaga A, Ciofani G. Innovative nanotechnology tools for the functional control and tracking of human stem cells. Mater Today Adv. 2022 Dec 1; 16.
Markstedt K, Mantas A, Tournier I, Martínez Ávila H, Hägg D, Gatenholm P. 3D bioprinting human chondrocytes with nanocellulose-alginate bioink for cartilage tissue engineering applications. Biomacromolecules. 2015 May 11; 16(5):1489–96.
Lumat, Y. (2023). Understanding the digital transformation in smes during the covid-19 pandemic and the effect on their business model. International Journal of Academic Research in Business and Social Sciences, 13(4).
Xu, Y., & Zhou, D. (2023). Feeling lonely, engaging online during the outbreak of COVID-19: A longitudinal study of Chinese older adults. Innovation in Aging, 7(7), igad090.
Aithal, P. S., & Aithal, S. (2023). Ubiquitous Education Technologies and Their Impact on Higher Education after COVID-19. Chapter, 2, 29-70.
Almeida, D., Dionísio, A., Vieira, I., & Ferreira, P. (2023). COVID-19 effects on the relationship between cryptocurrencies: can it be contagion? Insights from econophysics approaches. Entropy, 25(1), 98.
Jeong, K. O. (2023). Integrating technology into language teaching practice in the post-COVID-19 pandemic digital age: From a Korean English as a foreign language context. RELC Journal, 54(2), 394-409.
Aripin, Z., Matriadi, F., & Ermeila, S. (2023). INNOVATION WITH SMALL INDUSTRY PLAYERS TO CREATE SHARED VALUE IN THE EXPERIENCE OF THE COVID-19 PERIOD IN INDONESIA. Journal of Economics, Accounting, Business, Management, Engineering and Society, 1(1), 50-62.
Lim, K. Y., & Morris, D. (2023). Business optimism and the innovation-profitability nexus: Introducing the COVID-19 adaptable capacity framework. Research Policy, 52(1), 104623.
Creese, J., Byrne, J. P., Olson, R., & Humphries, N. (2023). A catalyst for change: Developing a collaborative reflexive ethnographic approach to research with hospital doctors during the COVID-19 pandemic. Methodological Innovations, 16(1), 3-14.
Almeida, F., & Wasim, J. (2023). The role of data-driven solutions for SMES in responding to COVID-19. International Journal of Innovation and Technology Management, 20(01), 2350001.
Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014; 107:84–94
Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020; 81(1):e21–e23.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020. In press.
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300(5626):1763–1767.
Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 Patients: a propensity score matched retrospective cohort study. Gastroenterology 2020; 159(3):1129–1131.e3.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with covid-19-preliminary report. N Engl J Med 2020. In press.
Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multi- centre, randomised controlled trial. Lancet Respir Med 2020; 8:267–276.
He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26:672– 675.
Hung IF, Lung KC, Tso EY, Liu R, Chung TW, and Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an openlabel, randomised, phase 2 trial. Lancet 2020; 395(10238):1695–1704.
Musumeci F, Greco C, Giacchello I, Fallacara AL, Ibrahim MM, Grossi G, et al. An update on JAK inhibitors. Curr Med Chem 2019; 26:1806–1832.
Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13:234–243.
Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, et al. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS Pathog 2017; 13:e1006740.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Bimalendu Pendy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
info@itscience.org, web: 
